

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/857,402 09/17/2001		Julio Cesar Aguilar Rubido	976-11 PCT/US	3056	
7	7590 01/28/2003				
Ronald J Baron			EXAMINER		
Hoffmann & Baron 6900 Jericho Turnpike			FOLEY, SH	FOLEY, SHANON A	
Syosset, NY	11791		ART UNIT	PAPER NUMBER	
			1648 DATE MAILED: 01/28/2003	14	

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)					
Advisory Action	09/857,402	AGUILAR RUBIDO ET AL.					
Auvisory Action	Examin r	Art Unit					
	Shanon Foley	1648					
Th MAILING DATE of this communication appears on the cover sheet with the correspondence address							
THE REPLY FILED 16 December 2002 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.							
PERIOD FOR RE	PLY [check either a) or b)]						
a) The period for reply expires 6 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee mave been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
 A Notice of Appeal was filed on <u>13 November 2002</u>. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal. 							
2. The proposed amendment(s) will not be entered because:							
(a) Methey raise new issues that would require further consideration and/or search (see NOTE below);							
(b) ☑ they raise the issue of new matter (see Note below);							
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or							
(d) they present additional claims without canceling a corresponding number of finally rejected claims.							
NOTE: See Continuation Sheet.							
3. Applicant's reply has overcome the following rejection(s):							
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).							
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:							
The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.							
The status of the claim(s) is (or will be) as follows:							
Claim(s) allowed: <u>none</u> . Claim(s) objected to: <u>none</u> . Claim(s) rejected: <u>11-33</u> .							
					Claim(s) withdrawn from consideration: none.	•	
					8. The proposed drawing correction filed on is	a) ☐ approved or b) ☐ disapp	proved by the Examiner.
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)							
10. ☐ Other:							
	١						

Continuation She t (PTO-303) 09/857,402

Continuation of 2. NOTE: The proposed amendment states that the second vaccine antigen has an adjuvanting effect on HBsAg, while the pending claims specify that the surface antigen has an adjuvanting effect on the second vaccine antigen. This discrepancy between the propsed amendment raises and the pending claims raises an issue of new matter and would require further consideration under 112

TECHNOLOGY CENTER 1600